November 22, 2016 - By Pete Kolinski · 0 Comments
MEDICAL TRANSCRIPTION BILLING (NASDAQ:MTBC) institutional sentiment increased to 2 in Q2 2016. Its up 1.80, from 0.2 in 2016Q1. The ratio is better, as 1 active investment managers increased and opened new equity positions, while 5 reduced and sold holdings in MEDICAL TRANSCRIPTION BILLING. The active investment managers in our partner’s database reported: 1.20 million shares, down from 1.21 million shares in 2016Q1. Also, the number of active investment managers holding MEDICAL TRANSCRIPTION BILLING in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 2 Increased: 0 New Position: 1.
Medical Transcription Billing, Corp
The stock decreased 3.78% or $0.035 on November 21, hitting $0.89. Medical Transcription Billing Corp (NASDAQ:MTBC) has declined 6.19% since April 20, 2016 and is downtrending. It has underperformed by 10.74% the S&P500.
According to Zacks Investment Research, “Medical Transcription Billing, Corp. is a healthcare information technology company. It engages in providing integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company offers revenue cycle, practice management services, patient scheduling, automated appointment reminders, e-prescribing, lab connectivity, and real-time insurance eligibility verification. Transcription Billing, Corp. is headquartered in Somerset, New Jersey.”
Jw Asset Management Llc holds 0.04% of its portfolio in Medical Transcription Billing Corp for 63,771 shares. Silverback Asset Management Llc owns 100,000 shares or 0.02% of their US portfolio. Moreover, Adage Capital Partners Gp L.L.C. has 0% invested in the company for 1.01 million shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Citadel Advisors Llc, a Illinois-based fund reported 17,785 shares.#img1#
Ratings analysis reveals 50% of Medical Transcription Billing’s analysts are positive. Out of 2 Wall Street analysts rating Medical Transcription Billing, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. MTBC was included in 3 notes of analysts from August 13, 2015. The rating was maintained by Chardan Capital Markets with “Buy” on Thursday, August 13. The rating was upgraded by Zacks on Friday, September 4 to “Hold”. Zacks downgraded the stock to “Hold” rating in Friday, August 28 report.
Medical Transcription Billing, Corp., incorporated on October 28, 2001, is a healthcare information technology firm that provides an integrated suite of Web solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform. PracticePro includes practice management software and related tools, which facilitate the day-to-day operation of a medical practice; electronic health records (EHR), which allow its clients to qualify for government incentives; revenue cycle management (RCM) services, which include medical billing, analytics and related services, and mobile Health (mHealth) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services.
Another recent and important Medical Transcription Billing Corp (NASDAQ:MTBC) news was published by Quotes.Wsj.com which published an article titled: “News Medical Transcription Billing Corp.MTBC” on August 30, 2012.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Pete Kolinski